ClinicalTrials.gg
CompletedNCT06733402Updated Dec 13, 2024

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

A Phase 1 interventional study of Trifarotene Cream 0.005% and AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG in Acne Vulgaris, sponsored by Taro Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Taro Pharmaceuticals USA (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.
  • Registered 5 months after the study started (first participant enrolled Jun 2024, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Enrollment
3rd of 12
1,000 · median 507
Started
2024
the only one that year
Phase 1
2 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
2 of 12
Taro Pharmaceuticals USA

Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 3rd largest by enrollment, is the only one that started in 2024, is one of 2 in phase 1, and was the 11th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of acne vulgaris.

Read the detailed description

A multi-center, double-blind, randomized, placebo-controlled, parallel-group study, comparing comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) to Aklief® Cream (US REFERENCE LISTED DRUG), Aklief Cream (REFERENCE PRODUCT) and each active treatment to a placebo control in the treatment of acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris.
  • Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3 or 4 as per the Investigator's Global Assessment (IGA).
  • Subjects must have ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) AND ≥ 20 inflammatory lesions (i.e., papules and pustules) AND ≤2 nodulocystic lesions (i.e., nodules and cysts), at baseline on the face.
  • Subjects must be willing to refrain from using all other topical acne medications or antibiotics for acne vulgaris during the 12-week treatment period, other than the product.

Exclusion criteria

Exclusion Criteria:

  • Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
  • Subjects with a history of or allergy to Trifarotene, retinoids and/or any of the study medication ingredients.
  • Subjects with excessive facial hair (e.g. beards, sideburns, mustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
  • Subjects with a baseline irritation score of 3 = severe (marked, intense).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,000 participants (actual)

Study arms

  • Experimental
    Trifarotene Cream 0.005%

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

    Drug: Trifarotene Cream 0.005%

  • Active comparator
    AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

    Drug: AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG

  • Active comparator
    AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

    Drug: AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT

  • Placebo comparator
    Placebo Control

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

    Drug: Placebo

Interventions

  • A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

    Also known as: Test Product

  • A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

    Also known as: Reference Product

  • DrugAKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT

    Drug page: Trifarotene

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

    Also known as: Reference Product

  • DrugPlacebo

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

    Also known as: Vehicle

06

What researchers measure

Primary outcomes

  1. Demonstrate the therapeutic equivalence, efficacy and safety of the Investigational Product

    Percentage change in the inflammatory (papules and pustules) \& non-inflammatory (open and closed comedones) of the lesion counts.

    Time frame: Baseline to Week 12

07

Study locations

1 site
  • Taro Pharmaceuticals USA Inc.
    Hawthorne, New York 10532, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jun 2024, 0 months.

Of 44 industry-sponsored phase 1 interventional studies under Acne Vulgaris, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 7. This study's 0 months is below that.

Counting every sponsor, half of 51 studies reached it within 5 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 13, 2024
StartActual
Jun 20, 2024
Primary completionActual
Jun 20, 2024
CompletionActual
Nov 9, 2024
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06733402
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Jun 20, 2024
Primary completion
Jun 20, 2024
Completion
Nov 9, 2024
Last update
Dec 13, 2024

Study contacts

Natalie Yantovskiy
study director · Taro Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion